ACR 2022 Tweet by Eric Dein

Ab0411 #ACR22 Bimekizumab in AS
P3 24 wk PBO control study BE-MOBILE 2

221 BKZ, 111 PBO
Wk 16 ASAS40: BKZ 45%, 22% PBO p<0.001
Efficacy in both TNF naive and TNF failure pts
Wk 24: 1/2 pts has ASDAS<2.1
Nasopharyngitis (6%), diarrhea (4%), h/a (3.6%) 👅candidiasis (3%)
@Rheumnow